Outpatient Treatment of Osteomyelitis with Telavancin


SUGAR LAND, TX (July 14, 2017) – Gram-positive osteomyelitis was successfully treated with telavancin, as published in an article in The International Journal of Antimicrobial Agents. Primary author was Claudia P. Schroeder, Clinical Research Lead at Healix®, in collaboration with treating physicians Robin H. Dretler, MD, of Infectious Disease Specialists of Atlanta, P.C., John S. Adams, MD, of Knoxville Infectious Disease Consultants, P.C., Richard C. Prokesch, MD, of Infectious Diseases Associates, Quyen Luu, MD, of Central Georgia Infectious Diseases Associates, Andrew H. Krinsky, MD, of Infectious Diseases Associates, and Lucinda J. Van Anglen, PharmD, Senior Vice President of Pharmacy, at Healix.


Telavancin is a lipoglycopeptide antibiotic with bactericidal activity against Gram-positive pathogens including Staphylococcus aureus, the most frequent cause of osteomyelitis. Treatment is often challenging due to needs for surgical intervention along with prolonged administration of intravenous antimicrobials, frequently in an outpatient setting. This was a retrospective analysis of the efficacy and safety of telavancin for treatment of osteomyelitis provided as outpatient parenteral antimicrobial therapy (OPAT) in physician office infusion centres. Medical records of 60 patients receiving telavancin for osteomyelitis in 22 physician office infusion centres from 2010 to 2011 and 2013 to 2015 were reviewed. Of these, 60% were treated without hospitalisation, 37% had orthopaedic hardware and 56% had concurrent infections. Staphylococcus aureus was the most common pathogen (78%), primarily methicillin-resistant. The median duration of telavancin treatment in the outpatient setting was 21 days (range 3–105 days). Telavancin was used as first-line therapy in 32% of cases, following prior antibiotic failure in 47% and due to intolerance to previous agents in 22%, predominantly daptomycin or vancomycin. The telavancin dose was 10 mg/kg/day, adjusted for renal function in 25% of patients. The majority of patients self-administered telavancin at home via an elastomeric infusion pump. Overall clinical success was 73%. No significant differences in outcomes were observed with the presence of hardware, concurrent infection, concomitant therapies or type of osteomyelitis. Telavancin-associated adverse events occurred in 57%, with discontinuation in three patients (5%). These data demonstrate the effective and safe OPAT use of telavancin, providing an alternative for successful treatment of patients with osteomyelitis.


The article is “Outpatient treatment of osteomyelitis with telavancin” by Claudia P. Schroeder, Lucinda J. Van Anglen, Robin H. Dretler, John S. Adams, Richard C. Prokesch, Quyen Luu, Andrew H. Krinsky (doi: 10.1016/j.ijantimicag.2017.01.034). It appears in The International Journal of Antimicrobial Agents, Volume 50, Issue 1, 93 – 96 (2017), published by Elsevier.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.